pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·8h ago·1 min read
save

Seven new tumor cases reported in Zolgensma patients

Nine patients who have received Novartis' spinal muscular gene therapy Zolgensma have developed tumors following their treatment, the company confirmed Thursday. Seven of those cases were disclosed for the first time. Two may be linked ...

Nov 5, 2026·read at Endpoints ↗

November 5, 2026 04:08 PM EST R&DCell/Gene Tx Sev­en new tu­mor cas­es re­port­ed in Zol­gens­ma pa­tients Lei Lei Wu News Reporter Nine pa­tients who have re­ceived No­var­tis’ spinal mus­cu­lar gene ther­a­py Zol­gens­ma have de­vel­oped tu­mors fol­low­ing their treat­ment, the com­pa­ny con­firmed Thurs­day. Sev­en of those cas­es … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
81 words · retrieved 7h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVARTIS
topics
Gene Therapy (AAV)Oncology

related stories

  • 15h agoNovartis subsidiary Avidity will lay off 40 in San DiegoBioSpace
  • Sep 23Roche, Ionis RNA drug scores in kidney disease studyBioPharma Dive
  • Sep 20STAT+: Radiopharma companies merge after one receives surprise FDA rejectionSTAT
  • Sep 17Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialFierce Biotech
  • Sep 14Cellectis quits CAR-T and pivots to ‘in vivo’ gene editingBioPharma Dive